{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:09:10Z","timestamp":1762916950454},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.cct.2005.02.001","type":"journal-article","created":{"date-parts":[[2005,3,30]],"date-time":"2005-03-30T12:19:22Z","timestamp":1112185162000},"page":"349-364","source":"Crossref","is-referenced-by-count":17,"title":["A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials"],"prefix":"10.1016","volume":"26","author":[{"given":"David B.","family":"Hall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Cristoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2005.02.001_bib1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1046\/j.1526-4610.1998.3803184.x","article-title":"Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan","volume":"38","author":"Pfaffenrath","year":"1998","journal-title":"Headache"},{"issue":"Suppl. 1","key":"10.1016\/j.cct.2005.02.001_bib2","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1007\/BF01642909","article-title":"Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study","volume":"238","author":"Patten","year":"1991","journal-title":"J Neurol"},{"key":"10.1016\/j.cct.2005.02.001_bib3","series-title":"Drug treatment of migraine and other frequent headaches","first-page":"134","article-title":"Treatment of acute migraine attacks with naratriptan","author":"Goadsby","year":"2000"},{"key":"10.1016\/j.cct.2005.02.001_bib4","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0149-2918(00)80068-5","article-title":"Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study","volume":"22","author":"Havanka","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.cct.2005.02.001_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-8993(93)90591-A","article-title":"Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater","volume":"626","author":"Lee","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.cct.2005.02.001_bib6","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1476-5381.1991.tb09805.x","article-title":"Further characterisation of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater","volume":"103","author":"Buzzi","year":"1991","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cct.2005.02.001_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/1531-8249(200002)47:2<238::AID-ANA15>3.0.CO;2-L","article-title":"No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials","volume":"47","author":"Roon","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cct.2005.02.001_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/sj.bjp.0703110","article-title":"Pharmacological profile of BIBN-4096BS, the first selective small molecule CGRP antagonist","volume":"129","author":"Doods","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cct.2005.02.001_bib9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0028-3908(02)00008-4","article-title":"Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment","volume":"42","author":"Moreno","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cct.2005.02.001_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000116757","article-title":"Methodology of clinical trials of sumatriptan in migraine and cluster headache","volume":"31","author":"Pilgrim","year":"1991","journal-title":"Eur Neurol"},{"key":"10.1016\/j.cct.2005.02.001_bib11","series-title":"Guidelines for controlled trials of drugs in migraine","first-page":"765","volume":"vol. 20","author":"Tfelt-Hansen","year":"2000"},{"key":"10.1016\/j.cct.2005.02.001_bib12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1468-2982.1999.019008699.x","article-title":"Unbalanced randomisation influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials","volume":"19","author":"Diener","year":"1999","journal-title":"Cephalalgia"},{"key":"10.1016\/j.cct.2005.02.001_bib13","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT1B\/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials","volume":"358","author":"Ferrari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2005.02.001_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1468-2982.2003.00549.x","article-title":"Effect of active control is lower when using placebo control in clinical trials on acute therapy of migraine","volume":"23","author":"Eikermann","year":"2003","journal-title":"Cephalalgia"},{"key":"10.1016\/j.cct.2005.02.001_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/sim.4780140909","article-title":"An extension of the continual reassessment methods using a preliminary up and down design in a dose finding study in cancer patients, in order to investigate a greater range of doses","volume":"14","author":"M\u00f8ller","year":"1995","journal-title":"Stat Med"},{"key":"10.1016\/j.cct.2005.02.001_bib16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2005.02.001_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2307\/2533975","article-title":"A random walk rule for phase I clinical trials","volume":"53","author":"Durham","year":"1997","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2005.02.001_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.0006-341X.2002.00171.x","article-title":"Dose finding using a biased coin up-and-down design and isotonic regression","volume":"58","author":"Stylianou","year":"2002","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2005.02.001_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/sim.1336","article-title":"Improved up-and-down designs for phase I trials","volume":"22","author":"Ivanova","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.cct.2005.02.001_bib20","series-title":"Le plan d'experience","first-page":"181","article-title":"Sequential experiments for estimating the median lethal dose","author":"Cochran","year":"1963"},{"key":"10.1016\/j.cct.2005.02.001_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10543409408835069","article-title":"Sequential method of estimating the LD50 using a modified up-and-down rule","volume":"4","author":"Jung","year":"1994","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.cct.2005.02.001_bib22","series-title":"Group sequential methods with applications to clinical trials","author":"Jennison","year":"2000"},{"issue":"3","key":"10.1016\/j.cct.2005.02.001_bib23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1081\/BIP-100101190","article-title":"The distribution of the maximum likelihood estimator in up-and-down experiments for quantal dose\u2013response data","volume":"9","author":"V\u00e5ger\u00f6","year":"1999","journal-title":"J Biopharm Stat"},{"issue":"11","key":"10.1016\/j.cct.2005.02.001_bib24","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714405000443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714405000443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T21:54:41Z","timestamp":1548626081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714405000443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S1551714405000443"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2005.02.001","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}